Clinical trials in Legnago – page 2

21 clinical trials in Legnago, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Legnago at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

21 trials in Legnago

Open in trial search

Fallopian tube cancer+2

Not recruiting

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo

Study of Relacorilant and Nab-Paclitaxel for Patients with Advanced, Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Relacorilant
Sponsor:Corcept Therapeutics Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on the Effect of Cemiplimab in Patients with Oligometastatic Non-Small Cell Lung Cancer After Radical Treatment

Registered drug

Study on the Effect of Cemiplimab in Patients with Oligometastatic Non-Small Cell Lung Cancer After Radical Treatment

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Malignant peritoneal neoplasm+2

Not recruiting

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Registered drugNo placebo

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Hormone receptor positive breast cancer

Not recruiting

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Anastrozole
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer stage IV

Not recruiting

Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Favezelimab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Baricitinib
Sponsor:Oslo University Hospital HF

Contact Research Centre

Adenocarcinoma of colon

Not recruiting

Study of Durvalumab and Regorafenib for Patients with Stage IV Colorectal Cancer with No Evidence of Disease

Registered drugNo placebo

Study of Durvalumab and Regorafenib for Patients with Stage IV Colorectal Cancer with No Evidence of Disease

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:IRCCS Ospedale Policlinico San Martino

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Legnago

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer treatments, particularly evaluating combination therapies including immunotherapy approaches and targeted treatments.

Advanced NSCLC Treatment
Immunotherapy Combinations
Second-line Therapy Evaluation

Studies are examining novel treatment combinations with pembrolizumab and other immunotherapy agents for improved patient outcomes.

02 Breast Cancer Studies

Comprehensive research into early breast cancer treatments, with particular focus on hormone receptor-positive and HER2-negative disease variants.

Endocrine Therapy Innovation
BRCA-Related Research
Targeted Therapies

Trials are evaluating new therapeutic approaches including adjuvant treatments and novel drug combinations.

03 Ovarian Cancer Research

Advanced studies examining treatments for recurrent ovarian cancer and related conditions, with emphasis on maintenance therapy approaches.

BRCA Wild-Type Studies
Maintenance Therapy
Biomarker Research

Investigations focus on improving treatment outcomes through targeted therapies and personalized approaches.

04 Colorectal Cancer Initiatives

Studies addressing advanced colorectal cancer treatment strategies, including targeted therapies and novel drug combinations.

Metastatic Disease Management
Liquid Biopsy Applications
Adjuvant Treatment Optimization

Research focuses on personalized treatment approaches based on genetic markers and disease staging.

Back to Italy All countries